Orphan Drug Designation Granted by the U.S. FDA for SL-172154 for the Treatment of AML
“AML patients have few options for treatment and a poor prognosis. FDA’s decision to grant orphan drug designation to SL-172154 highlights the urgent need for new treatment options,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “This is an important first step in our progression to later-stage clinical studies, and we look forward to presenting additional data from the Phase 1B dose expansion clinical trial of SL-172154 with azacitidine in frontline higher-risk myelodysplastic syndromes and TP53m AML patients during a poster presentation at the European Hematology Association 2024 Congress.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.